Amruta specialises in the development of hybrid nanosystems for improved intracellular drug delivery over singular systems

​Amruta currently investigates the possibility of developing and optimising hybrid nanosystems that encompass biological and synthetic nanoparticles for drug delivery. Her aim is to develop a platform that outperforms single systems for efficient intracellular drug delivery, by leveraging the synergestic potential between extracellular vesicles and lipid-based synthetic nanoparticles. A 'best-of-both-worlds' approach, this would ideally allow for the platform to be used in a multidisciplinary manner for the treatment of several diseases, including cancer and diabetes. 

​Amruta first completed her Bachelor's in Bioengineering at Nanyang Technological University (2016-2020), where she was part of the CN Yang Scholars' Program. In cumulation to honing her research skills, this allowed her to pursue her thesis at the Lab of Biomaterials for Immunoengineering in École polytechnique fédérale de Lausanne (EPFL), Switzerland. Her thesis was focused on the targeted delivery of IL-15 Superagonist expressed by T Cells in solid tumors for enhanced cancer immunotherapy. Subsequently, she graduated from The University of Queensland with a Master's in Medical Biotechnology (2022-2023), where she explored the development of biological-synthetic hybrid systems for drug delivery as part of her thesis. Alongside furthering her academic ventures, Amruta has also worked in industry for 2 years, at reputable entities including Merck Sharp & Dohme (2020) and Agency for Science, Technology and Research (A*STAR) (2020-2021) in Singapore.

Key Publications

​Amruta A, Iannotta D, Cheetham SW, Lammers T, Wolfram J. Vasculature organotropism in drug delivery [published online ahead of print, 2023 Aug 15]. Adv Drug Deliv Rev. 2023;201:115054. doi:10.1016/j.addr.2023.115054